Role of conventional salvage multiple-drug chemotherapy in relapsed and refractory aggressive non-Hodgkin lymphomas

Gobbi,Paolo G.; Villano,Lara; Pozzoli,Donatella; Bergonzi,Manuela

doi:10.3892/ol_00000119

Role of conventional salvage multiple-drug chemotherapy in relapsed and refractory aggressive non-Hodgkin lymphomas

Authors:
- Paolo G. Gobbi
- Lara Villano
- Donatella Pozzoli
- Manuela Bergonzi
View Affiliations

Affiliations: Clinica Medica I, Università di Pavia, Fondazione IRCCS Policlinico S. Matteo, 27100 Pavia, Italy. gobbipg@smatteo.pv.it
Published online on: July 1, 2010 https://doi.org/10.3892/ol_00000119
Pages: 679-683

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Autologous stem cell transplantation is the standard care for patients with relapsed or refractory aggressive non-Hodgkin lymphomas. Of the patients who are sensitive to second-line chemotherapy, approximately 40-50% are likely to be cured using this approach. The optimal salvage regimen for pre-transplant debulking is controversial and these second-line chemotherapies are particularly important for patients who cannot undergo transplantation for various reasons including age, comorbidity and insufficient stem cell collection. Numerous reports regarding this topic are available. This study evaluated reports published in the last 5 years, focusing on conventional multiple-drug second-line chemotherapies (with or without rituximab), and disregarding single-agent investigational phase-II trials. Results are encouraging, particularly when considering that the more recent and less toxic combinations appear to be equivalent to or even more favourable than previous, more aggressive approaches. Previous results obtained using a combination of mitoxantrone, carboplatin, cytarabine and methylprednisolone, are further updated and included in this study. In conclusion, the most effective conventional chemotherapy currently available for patients with relapsed or refractory non-Hodgkin lymphomas obtains complete remission rates of up to 50-70%; the achievement of a complete remission is the most important factor associated with a better outcome. Although the addition of rituximab is beneficial and safe, it is more effective in patients who have previously not been exposed to this monoclonal antibody. The addition of cycles of salvage chemotherapy to those strictly required for mobilization of peripheral blood stem cells ultimately improves the response rate.

View Figures

View References

1	Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 328:1002–1006. 1993.PubMed/NCBI
2	Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 346:235–242. 2002. View Article : Google Scholar : PubMed/NCBI
3	Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemosensitive non-Hodgkin’s lymphoma. N Engl J Med. 333:1540–1545. 1995.PubMed/NCBI
4	Ardeshna KM, Kakouros N, Qian W, et al: Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. Br J Haematol. 130:363–372. 2005. View Article : Google Scholar
5	Casasnovas RO, Haioun C, Dumontet C, et al: Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin’s lymphomas. Groupe d’Etude des Lymphomes de l’Adulte. Haematologica. 85:502–507. 2000.PubMed/NCBI
6	Gobbi PG, Valentino F, Lambelet P, et al: Shortened and intensified MJMA: an effective salvage therapy for relapsed and refractory lymphomas and a strong mobilizer of PBSCs. Bone Marrow Transplant. 44:19–25. 2009. View Article : Google Scholar : PubMed/NCBI
7	Sica S, Di Mario A, Salutari P, et al: Sequential peripheral blood progenitor cell transplantation after mobilization with salvage chemotherapy and G-CSF in patients with resistant lymphoma. Am J Hematol. 46:18–23. 1994. View Article : Google Scholar : PubMed/NCBI
8	La Barbera EO, Chiusolo P, Laurenti L, et al: MiCMA: an alternative treatment for refractory or recurrent Hodgkin’s disease. Ann Oncol. 11:867–871. 2000.
9	Oyan B, Koc Y, Ozdemir E, et al: Ifosfamide, idarubicin and etoposide in relapsed/refractory Hodgkin disease and non-Hodgkin lymphomas: a salvage regimen with high response rates before autologous stem cell transplantation. Biol Blood Marrow Transplant. 11:688–697. 2005. View Article : Google Scholar
10	Zhou SY, Shi YK, He XH, et al: Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high-grade non-Hodgkin’s lymphoma. Ai Zheng. 24:465–469. 2005.
11	Clavio M, Garrone A, Pierri I, et al: Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: A feasible and effective salvage treatment for lymphoid malignancies. Oncol Rep. 14:933–940. 2005.
12	Menzel H, Müller A, von Schilling C, Licht T, Peschel C and Keller U: Ifosfamide, epirubicin and etoposide rituximab in refractory or relapsed B-cell lymphoma: analysis of remission induction and stem cell mobilization. Leuk Lymphoma. 49:1337–1344. 2008. View Article : Google Scholar : PubMed/NCBI
13	Bishton MJ, Lush RJ, Byrne JL, Russell NH, Shaw BE and Haynes AP: Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. Br J Haematol. 36:752–761. 2007. View Article : Google Scholar
14	Hertzberg MS, Crombie C, Benson W, Taper J, Gottlieb D and Bradstock KF: Outpatient fractionated ifosfamide, carboplatin, and etoposide as salvage therapy in relapsed and refractory non-Hodgkin’s lymphoma. Ann Oncol. 17(Suppl 4): 25–30. 2006.
15	Aurer I, Metrovic Z, Nemet D, et al: Treatment of relapsed or refractory aggressive non-Hodgkin lymphoma with two ifosfamide-based regimens, IMVP and ICE. J Chemother. 20:640–644. 2008. View Article : Google Scholar : PubMed/NCBI
16	Simpson L, Ansell SM, Colgan JP, et al: Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cisplatinum, cytosine arabinoside and dexamethasone. Leuk Lymphoma. 48:1332–1337. 2007. View Article : Google Scholar
17	Kewalramani T, Zelenetz AD, Nimer SD, et al: Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 103:3684–3688. 2004. View Article : Google Scholar : PubMed/NCBI
18	Shütt P, Passon J, Ebeling P, et al: Ifosfamide, etoposide, cytarabine and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. Eur J Haematol. 78:93–101. 2007.
19	Müller-Beissenhirtz H, Kasper C, Nückel H and Dührsen U: Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, result of a phase II single center study. Ann Hematol. 84:796–801. 2005.PubMed/NCBI
20	Papageorgiou ES, Tsirigotis P, Dimopoulos M, et al: Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: a phase-II trial by the Hellenic Cooperative Oncology Group. Eur J Haematol. 75:124–129. 2005. View Article : Google Scholar
21	Avilès A, Neri N, Huerta-Guzman J and Fernandez R: Gemcitabine and cisplatin in refractory malignant lymphoma. Oncology. 66:197–200. 2004.PubMed/NCBI
22	Crump M, Baetz T, Couban S, et al: Gemcitabine, dexamethasone and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma. Cancer. 101:1835–1842. 2004. View Article : Google Scholar : PubMed/NCBI
23	Fan Y, Huang ZY, Luo LH and Yu HF: Efficacy of GDP regimen (gemcitabine, dexamethasone and cisplatin) on relapsed or refractory aggressive non-Hodgkin’s lymphoma: a report of 24 cases. Ai Zheng. 27:1222–1225. 2008.
24	Di Renzo N, Brugnatelli M, Montanini A, et al: Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractorry aggressive non-Hodgkin’s lymphoma: results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi. Leuk Lymphoma. 47:473–479. 2006.
25	Corazzelli G, Russo F, Capobianco G, Marcacci G, Della Cioppa P and Pinto A: Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin’s lymphoma: results of a pilot study. Ann Oncol. 17(Suppl 4): 18–24. 2006.PubMed/NCBI
26	Lòpez A, Gutierrez A, Palacios A, et al: GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. Eur J Haematol. 80:127–132. 2007.PubMed/NCBI
27	Ng M, Waters J, Cunnigham D, et al: Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer. 92:1352–1357. 2005. View Article : Google Scholar : PubMed/NCBI
28	Sirohi B, Cunningham D, Norman A, et al: Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without rituximab in relapsed and refractory patients with diffuse large B-cell lymphoma. Hematology. 12:149–153. 2007. View Article : Google Scholar : PubMed/NCBI
29	Oki Y, Pro B, Fayad LE, et al: Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer. 112:831–836. 2008. View Article : Google Scholar : PubMed/NCBI
30	Olivieri A, Brunori M, Capelli D, et al: Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis. Eur J Haematol. 72:10–17. 2004. View Article : Google Scholar : PubMed/NCBI
31	Mey UJ, Orlopp KS, Flieger D, et al: Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin’s lymphoma. Cancer Invest. 24:593–600. 2006.
32	Josting A, Sieniawski M, Glossmann JP, et al: High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed or refractory aggressive non-Hodgkin’s lymphoma: results of a multicentric phase II study. Ann Oncol. 16:1359–1365. 2005.
33	Vellenga E, van Putten WL, van’t Veer MB, et al: Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20⁺ NHL: a prospective randomized HOVON trial. Blood. 111:537–543. 2008. View Article : Google Scholar : PubMed/NCBI
34	Park SH, Kim S, Ko OB, et al: ESHAP salvage therapy for refractory and relapsed non-Hodgkin’s lymphoma: a single center experience. Korean J Intern Med. 21:159–164. 2006.
35	Martin A, Conde E, Arnan M, et al: R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse lsrge B-cell lymphoma: the influence of prior exposure to rituximab on outcome. Haematologica. 93:1829–1836. 2008. View Article : Google Scholar : PubMed/NCBI
36	Sorà F, Piccirillo N, Chiusolo P, et al: Mitoxantrone, carboplatin, cytosine arabinoside, and methylprednisolone followed by autologous peripheral blood stem cell transplantation. Cancer. 106:859–866. 2006.PubMed/NCBI
37	Atta J, Chow KU, Weidmann E, Mitrou PS, Hoelzer D and Martin H: Dexa-BEAM as salvage therapy in patients with primary refractory aggressive non-Hodgkin lymphoma. Leuk Lymphoma. 48:349–356. 2007. View Article : Google Scholar : PubMed/NCBI
38	Jermann M, Jost LM, Taverna CH, et al: Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol. 15:511–516. 2004. View Article : Google Scholar : PubMed/NCBI
39	Wang M, Fayad L, Cabanillas F, et al: Phase-2 trial of rituximab plus HyperCVAD alternating with rituximab plus methotrexate – cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer. 113:2734–2741. 2008.
40	Robak T, Lech-Maranda E, Janus A, Blonski J, Wierzbowska A and Gora-Tybor J: Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin’s lymphoma. Leuk Lymphoma. 48:1092–1101. 2007.
41	Zwick C, Birkmann J, Peter N, et al: Equitoxicity of bolus and infusional etoposide: results of a multi center randomised trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone). Ann Hematol. 87:717–726. 2008.
42	Sud R and Friedberg JW: Salvage therapy for relapsed or refractory diffuse large B-cell lymphoma: impact of prior rituximab. Haematologica. 93:1776–1780. 2008. View Article : Google Scholar : PubMed/NCBI